Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction

Progress in hematology


Graft-versus-host disease (GVHD) is the major complication after allogeneic hemopoietic stem cell transplantation. GVHD is destructive by itself and sets the stage for other sequelae, in particular, overwhelming infections. Recent investigations have improved our understanding of the underlying pathophysiology of GVHD. There are now compelling data on the role of host tissue destruction as the initial insult, extensive interactions of cellular donor and host components, a complex network of cytokines, adhesion molecules, and other components in the development of GVHD. The improved understanding of interactions among various signals is likely to allow for the development of new prophylactic strategies. A review of the data shows, however, that results are very dependent upon the models used. It is difficult or impossible to separate completely the discussion of cytokines that affect hemopoietic cells from discussion of cytokines that exert effects on immune cells. Furthermore, secondary effects on immune cells via hemopoietic cells complicate the picture. Application of the principles of cytokine signaling to the clinical setting may necessitate new trial design structures that take into consideration donor and host characteristics as well as the kinetics of GVHD development.

Key words

GVHD Cytokines Network 


  1. 1.
    Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease [review].Biol Blood Marrow Transplant. 1999;5:347–356.PubMedCrossRefGoogle Scholar
  2. 2.
    Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.J Clin Invest. 1999;104:459–467.PubMedCrossRefGoogle Scholar
  3. 3.
    Xun CQ,Tsuchida M,Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation.Transplantation. 1997;64:297–302.PubMedCrossRefGoogle Scholar
  4. 4.
    Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines.Blood. 1997;90:3204–3213.PubMedGoogle Scholar
  5. 5.
    Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review].Blood. 2000;95:2754–2759.PubMedGoogle Scholar
  6. 6.
    Janossy G, Bofill M, Poulter LW, et al. Separate ontogeny of two macrophage-like accessory cell populations in the human fetus.J Immunol. 1986;136:4354–4361.PubMedGoogle Scholar
  7. 7.
    Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells.Science. 1999;285:412–415.PubMedCrossRefGoogle Scholar
  8. 8.
    Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies.Blood. 1998;91:4051–4055.PubMedGoogle Scholar
  9. 9.
    Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function.Proc Natl Acad Sci U S A. 1997;94:1366–1371.PubMedCrossRefGoogle Scholar
  10. 10.
    Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.J Clin Invest. 1997;100:904–911.PubMedCrossRefGoogle Scholar
  11. 11.
    Hiroyasu S, Shiraishi M, Koji T, et al. Analysis of Fas system in pulmonary injury of graft-versus-host disease after rat intestinal transplantation.Transplantation. 1999;68:933–938.PubMedCrossRefGoogle Scholar
  12. 12.
    Lesnikova M, Lesnikov V, Arrighi S, Kistler G, Pierpaoli W, Deeg HJ. Upregulation of interleukin-10 and inhibition of alloantigen responses by transferrin and transferrin-derived glycans.J Hematother Stem Cell Res. 2000;9:381–392.PubMedCrossRefGoogle Scholar
  13. 13.
    Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease.J Immunol. 1999;162:4373–4376.PubMedGoogle Scholar
  14. 14.
    Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.J Immunol. 1998;160:4225–4231.PubMedGoogle Scholar
  15. 15.
    Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.Blood. 2000;95:2434–2439.PubMedGoogle Scholar
  16. 16.
    Schultz KR, Paquet J, Bader S, Hayglass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.Bone Marrow Transplant. 1995;16:289–295.PubMedGoogle Scholar
  17. 17.
    Schwaighofer H, Oberhuber G, Hebart H, et al. Endogenous inter-leukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.Transplantation. 1997;63:52–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.Blood. 1994;84:1342–1348.PubMedGoogle Scholar
  19. 19.
    Hill GR, Cooke KR, Brinson YS, Bungard D, Ferrara JL. Pretransplant chemotherapy reduces inflammatory cytokine production and acute graft-versus-host disease after allogeneic bone marrow transplantation.Transplantation. 1999;67:1478–1480.PubMedCrossRefGoogle Scholar
  20. 20.
    Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd Edition Revised and Expanded. New York, NY: Marcel Dekker, Inc., 1997:257–290.Google Scholar
  21. 21.
    Kozlowski T, Sablinski T, Basker M, et al. Decreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatment.Bone Marrow Transplant. 2000;25:47–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Jadus MR, Websic HT. The role of cytokines in graft-versus-host reactions and disease.Bone Marrow Transplant. 1992;10:1–14.PubMedGoogle Scholar
  23. 23.
    Clancy JJ, Goral J, Kovacs EJ, Ellis T. Role of recombinant inter-leukin-2 (rIL-2) and large granular lymphocytes (LGLs) in acute rat graft-versus-host disease (GVHD).Transplant Proc. 1989;21:88–89.PubMedGoogle Scholar
  24. 24.
    Hervé P, Wijdenes J, Bergerat JP, Milpied N, Gaud C, Bordigoni P. Treatment of acute graft-versus-host disease with monoclonal antibody to IL-2 receptor.Lancet. 1988;2:1072–1073.PubMedCrossRefGoogle Scholar
  25. 25.
    Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease.Transplantation. 1990;50:49–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.Blood. 2000;95:83–89.PubMedGoogle Scholar
  27. 27.
    Lankford KV, Mosunjac M, Hillyer CD. Effects of UVB radiation on cytokine generation, cell adhesion molecules, and cell activation markers in T-lymphocytes and peripheral blood HPCs.Transfusion. 2000;40:361–367.PubMedCrossRefGoogle Scholar
  28. 28.
    Uharek L, Glass B, Zeis M, et al. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).Exp Hematol. 1998;26:93–99.PubMedGoogle Scholar
  29. 29.
    Klingemann H-G, Eaves CJ, Barnett MJ, et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by inter-leukin-2 administration.Bone Marrow Transplant. 1994;14:389.PubMedGoogle Scholar
  30. 30.
    Meehan KR, Verma UN, Cahill R, et al. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.Bone Marrow Transplant. 1997;20:643–651.PubMedCrossRefGoogle Scholar
  31. 31.
    Murphy WJ,Welniak LA,Taub DD, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.J Clin Invest. 1998;102:1742–1748.PubMedCrossRefGoogle Scholar
  32. 32.
    Krenger W, Rossi S, Piali L, Hollander GA. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells.Blood. 2000;96:347–354.PubMedGoogle Scholar
  33. 33.
    Nawa Y, Teshima T, Sunami K, et al. G-CSF reduces IFN-gamma and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function.Bone Marrow Transplant. 2000;25:1035–1040.PubMedCrossRefGoogle Scholar
  34. 34.
    King C, Mueller HR, Malo CM, et al. Interleukin-4 acts at the locus of the antigen-presenting dendritic cell to counter-regulate cyto-toxic CD8+ T-cell responses.Nat Med. 2001;7:206–214.PubMedCrossRefGoogle Scholar
  35. 35.
    Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.J Clin Invest. 2000;105:1289–1298.PubMedCrossRefGoogle Scholar
  36. 36.
    del Rosario ML, Zucali JR, Kao KJ. Prevention of graft-versus-host disease by induction of immune tolerance with ultraviolet B-irradiated leukocytes in H-2 disparate bone marrow donor.Blood. 1999;93:3558–3564.PubMedGoogle Scholar
  37. 37.
    Imoto S, Oomoto Y, Murata K, et al. Kinetics of serum cytokines after allogeneic bone marrow transplantation: interleukin-5 as a potential marker of acute graft-versus-host disease.Int J Hematol. 2000;72:92–97.PubMedGoogle Scholar
  38. 38.
    Emmanouilides CE, Luo J, Baldwin G, et al. Murine IL-10 fails to reduce GVHD despite inhibition of alloreactivity in vitro.Bone Marrow Transplant. 1996;18:369–375.PubMedGoogle Scholar
  39. 39.
    Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE. Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL.Biol Blood Marrow Transplant. 1996;2:118–125.PubMedGoogle Scholar
  40. 40.
    Holler E, Roncarolo MG, Hintermeier-Knabe R, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation.Bone Marrow Transplant. 2000;25:237–241.PubMedCrossRefGoogle Scholar
  41. 41.
    Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation.Transplantation. 1998;66:863–871.PubMedCrossRefGoogle Scholar
  42. 42.
    Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.Blood. 1999;94:3941–3946.PubMedGoogle Scholar
  43. 43.
    Gorczynski RM, Chen Z, Zeng H, Gorczynski L, Terzioglu E. Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.Immunology. 1998;93:221–229.PubMedCrossRefGoogle Scholar
  44. 44.
    Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.J Clin Invest. 1998;102:115–123.PubMedCrossRefGoogle Scholar
  45. 45.
    Bozza M, Bliss JL, Maylor R, et al. Interleukin-11 reduces T-cell-dependent experimental liver injury in mice.Hepatology. 1999;30:1441–1447.PubMedCrossRefGoogle Scholar
  46. 46.
    Yang YG, Sykes M. The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD [review].Leukemia & Lymphoma. 1999;33:409–420.Google Scholar
  47. 47.
    Glass B, Uharek L, Hartung G, et al. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.Bone Marrow Transplant. 1998;21 (suppl 3):S3-S8.PubMedGoogle Scholar
  48. 48.
    Yabe M, Yabe H, Hattori K, et al. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.Bone Marrow Transplant. 1999;24:29–34.PubMedCrossRefGoogle Scholar
  49. 49.
    Kumaki S, Minegishi M, Fujie H, et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children.Int J Hematol. 1998;67:307–312.PubMedCrossRefGoogle Scholar
  50. 50.
    Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the production of CD4+ chronic myelogenous leukemia-specific allogeneic T lymphocytes.Cancer Res. 1997;57:1547–1553.PubMedGoogle Scholar
  51. 51.
    Busse WW, Lemanske RF. Advances in immunology — Asthma [review].N Engl J Med. 2001;344:350–62.PubMedCrossRefGoogle Scholar
  52. 52.
    Eissner G, Kohlhuber F, Grell M, et al. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin.Blood. 1995;86:4184–4193.PubMedGoogle Scholar
  53. 53.
    van den Brink MR, Moore E, Horndasch KJ, Crawford JM, Murphy GF, Burakoff SJ. Fas ligand-deficientgld mice are more susceptible to graft-versus-host-disease.Transplantation. 2000;70:184–191.PubMedGoogle Scholar
  54. 54.
    Miwa K, Hashimoto H, Yatomi T, Nakamura N, Nagata S, Suda T. Therapeutic effect of an anti-Fas ligand mAb on lethal graft-ver-sus-host disease.Int Immunol. 1999;11:925–931.PubMedCrossRefGoogle Scholar
  55. 55.
    Iwasaki T, Hamano T, Saheki K, et al. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells.Cell Immunol. 1999;197:30–38.PubMedCrossRefGoogle Scholar
  56. 56.
    Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants.Blood. 1998;92:3943–3948.PubMedGoogle Scholar
  57. 57.
    Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease.Blood. 1999;94:825–31.PubMedGoogle Scholar
  58. 58.
    Hervé P, Flesch M, Tiberghien J, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor α antibody for the treatment of refractory severe acute graft-versus-host disease.Blood. 1992;79:3362–3368.PubMedGoogle Scholar
  59. 59.
    Brok HP, Vossen JM, Heidt PJ. IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells.Bone Marrow Transplant. 1998;22:1005–1010.PubMedCrossRefGoogle Scholar
  60. 60.
    Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.Blood. 1997;90:4651–4660.PubMedGoogle Scholar
  61. 61.
    Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.J Immunol. 1998;161:2848–2855.PubMedGoogle Scholar
  62. 62.
    Sato K, Nagayama H, Takahashi TA. Aberrant CD3- and CD28- mediated signaling events in cord blood T cells are associated with dysfunctional regulation of Fas ligand-mediated cytotoxicity.J Immunol. 1999;162:4464–4471.PubMedGoogle Scholar
  63. 63.
    Rocha V, Wagner JE, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling.N Engl J Med. 2000;342:1846–1854.PubMedCrossRefGoogle Scholar
  64. 64.
    Iwasaki T, Hamano T, Saheki K, et al. Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.Immunology. 2000;99:94–100.PubMedCrossRefGoogle Scholar
  65. 65.
    Chester SJ, Esparza AR, Flinton LJ, Simon JD, Kelley RJ, Albala MM. Further development of a successful protocol of graft-versus-leukemia without fatal graft-versus-host disease in AKR mice.Cancer Res. 1979;37:3494–3496.Google Scholar
  66. 66.
    Mori T, Nishimura T, Ikeda Y, Hotta T, Yagita H, Ando K. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression.Blood. 1998;92:101–107.PubMedGoogle Scholar
  67. 67.
    van den Brink MR, Moore E, Horndasch KJ, et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease.J Immunol. 2000;164:469–480.Google Scholar
  68. 68.
    Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.Blood. 1999;93:2738–2747.PubMedGoogle Scholar
  69. 69.
    Ito M, Shizuru JA. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.Biol Blood Marrow Transplant. 1999;5:357–368.PubMedCrossRefGoogle Scholar
  70. 70.
    Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease.Transplantation. 1999;67:59–65.PubMedCrossRefGoogle Scholar
  71. 71.
    Asai O, Longo DL,Tian ZG, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.J Clin Invest. 1998;101:1835–1842.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  1. 1.Fred Hutchinson Cancer Research Center and University of WashingtonSeattle, WashingtonUSA

Personalised recommendations